Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is using “deceptive marketing” to sell copycat versions of its obesity blockbuster Wegovy.

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent mandate. Hims pushed back against the accusation.

Novo Nordisk has ended a partnership with U.S. telehealth company Hims & Hers, citing deceptive marketing and knock-off versions of its blockbuster weight-loss drug Wegovy. The Danish drugmaker announced Monday that Hims & Hers will no longer have direct access to Wegovy,